New drug combo aims to shrink tumors before cancer surgery

This study is testing if adding a new immunotherapy drug called treprizumab to standard chemotherapy before surgery is more effective for treating locally advanced head and neck cancer. It involves 122 patients who are randomly assigned to receive either the new combination or standard chemo alone for three cycles. The main goal is to see if the new combination leads to a better response, meaning more cancer cells are killed before the patient goes to surgery.